Published in J Pharm Sci on December 01, 2005
Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech (2008) 1.00
Electrophoretic particle guidance significantly enhances olfactory drug delivery: a feasibility study. PLoS One (2014) 0.86
Electrostatic charge effects on pharmaceutical aerosol deposition in human nasal-laryngeal airways. Pharmaceutics (2014) 0.83
Aerodynamic and electrostatic properties of model dry powder aerosols: a comprehensive study of formulation factors. AAPS PharmSciTech (2014) 0.75
Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols. Pharm Res (2017) 0.75
Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology (2012) 3.30
Responsiveness to three bronchial provocation tests in patients with asthma. Chest (2003) 1.49
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. J Pharm Sci (2006) 1.18
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci (2004) 1.17
In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv (2008) 1.15
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int J Pharm (2010) 1.11
Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev (2010) 1.11
Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res (2005) 1.10
How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res (2005) 1.08
In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech (2007) 1.07
Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med (2002) 1.06
Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv (2010) 1.05
What is a suitable dissolution method for drug nanoparticles? Pharm Res (2008) 1.01
Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulm Pharmacol Ther (2004) 1.00
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm (2008) 0.98
Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev (2011) 0.98
The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res (2005) 0.97
Coughing during mannitol challenge is associated with asthma. Chest (2004) 0.95
Liposomal formulations for inhalation. Ther Deliv (2013) 0.94
A simple relationship between dielectric constant of mixed solvents with solvent composition and temperature. Int J Pharm (2004) 0.94
Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects. Respirology (2005) 0.94
The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci (2008) 0.92
SPECT Imaging for Radioaerosol Deposition and Clearance Studies. J Aerosol Med (2006) 0.92
Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Pharm Res (2007) 0.91
Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res (2007) 0.91
Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res (2010) 0.90
Effect of powder polydispersity on aerosol generation. J Pharm Pharm Sci (2002) 0.89
Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci (2005) 0.89
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics. Eur J Pharm Biopharm (2007) 0.87
Inhaled antibiotics to treat lung infection. Pharm Pat Anal (2013) 0.87
Solubility prediction in supercritical CO(2) using minimum number of experiments. J Pharm Sci (2002) 0.87
Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci (2008) 0.86
Modifying the release properties of liposomes toward personalized medicine. J Pharm Sci (2014) 0.86
The use of computational approaches in inhaler development. Adv Drug Deliv Rev (2011) 0.86
Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®). AAPS J (2013) 0.86
Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest (2003) 0.86
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci (2010) 0.84
Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. J Pharm Biomed Anal (2009) 0.84
Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers? Pharm Res (2012) 0.84
Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci (2011) 0.84
Recent advances in controlled release pulmonary therapy. Curr Drug Deliv (2009) 0.83
Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties. AAPS PharmSciTech (2014) 0.83
Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci (2010) 0.83
Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). Eur J Pharm Sci (2009) 0.83
The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med (2002) 0.82
The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci (2007) 0.82
Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci (2008) 0.82
Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm (2007) 0.81
Isoniazid induces its own resistance in nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2007) 0.81
Electrostatics of pharmaceutical inhalation aerosols. J Pharm Pharmacol (2009) 0.80
Lactose composite carriers for respiratory delivery. Pharm Res (2008) 0.80
Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler. J Aerosol Med Pulm Drug Deliv (2013) 0.80
Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther Deliv (2010) 0.80
Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. J Pharm Sci (2011) 0.80
Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J Pharm Sci (2009) 0.80
Electrostatics in pharmaceutical aerosols for inhalation. Ther Deliv (2013) 0.80
Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv (2012) 0.80
A solid-state NMR study of protein mobility in lyophilized protein-sugar powders. J Pharm Sci (2002) 0.80
Impact angles as an alternative way to improve aerosolisation of powders for inhalation? Eur J Pharm Sci (2010) 0.79
Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm (2004) 0.79
Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int J Pharm (2012) 0.79
Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols. Pharm Res (2007) 0.79
Effect of crystallinity on electrostatic charging in dry powder inhaler formulations. Pharm Res (2014) 0.78
Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance. J Aerosol Med Pulm Drug Deliv (2012) 0.78
Powder Production and Particle Engineering for Dry Powder Inhaler Formulations. Curr Pharm Des (2015) 0.78
Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles. AAPS J (2009) 0.78
Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance. J Pharm Sci (2011) 0.78
Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying. Pharm Res (2013) 0.78
Multi-scale modelling of powder dispersion in a carrier-based inhalation system. Pharm Res (2014) 0.78
Electrostatic charge characteristics of jet nebulized aerosols. J Aerosol Med Pulm Drug Deliv (2010) 0.78
The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems. Pharm Res (2010) 0.78
Inhalation challenge with bovine dander allergens: who needs it? Chest (2003) 0.77
Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm (2010) 0.77
Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm Res (2010) 0.77
Solubility prediction of paracetamol in binary and ternary solvent mixtures using Jouyban-Acree model. Chem Pharm Bull (Tokyo) (2006) 0.77
Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm (2011) 0.77
Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech (2014) 0.77
Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci (2008) 0.77
TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine (2013) 0.77
The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Drug Dev Ind Pharm (2013) 0.77
Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. Int J Pharm (2013) 0.77
Method to introduce mannitol powder to intubated patients to improve sputum clearance. J Aerosol Med Pulm Drug Deliv (2010) 0.77
Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int J Pharm (2006) 0.77
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci (2009) 0.76
Nanodrug particles and nanoformulations for drug delivery. Adv Drug Deliv Rev (2011) 0.76
Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. Pharm Res (2008) 0.76
Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system. Pharm Res (2003) 0.76
Pulmonary drug delivery. Ther Deliv (2013) 0.76
A novel inhalable form of rifapentine. J Pharm Sci (2014) 0.76
Does electrostatic charge affect powder aerosolisation? J Pharm Sci (2010) 0.76
Evaluation on the use of confined liquid impinging jets for the synthesis of nanodrug particles. Drug Dev Ind Pharm (2008) 0.76
Fabrication of inhalable spore like pharmaceutical particles for deep lung deposition. Int J Pharm (2012) 0.75
The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. Pharm Res (2009) 0.75
The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering. Expert Opin Drug Deliv (2014) 0.75
Unitary hormonal models, peripheral markers, and evaluation of response to drug: a response to Weisman and Feldman. Psychoneuroendocrinology (2013) 0.75
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy. J Pharm Sci (2014) 0.75
A cosolvency model to predict solubility of drugs at several temperatures from a limited number of solubility measurements. Chem Pharm Bull (Tokyo) (2002) 0.75
Mathematical representation of apparent dissociation constants in aqueous-organic solvent mixtures. Int J Pharm (2002) 0.75
A novel method for the production of crystalline micronised particles. Int J Pharm (2010) 0.75